Adolor Corporation to Present at the Ninth Annual Needham Healthcare Conference

Adolor Corporation (NasdaqGM: ADLR) today announced that management will present at the Ninth Annual Needham Healthcare Conference on Wednesday, June 9, 2010 at 11:20 A.M. Eastern Daylight Time. The conference is being held at The New York Palace Hotel, New York City, New York.

Adolor’s presentation will be webcast live on the investor relations section of the Company’s website and will be archived for one week following the broadcast. To access the webcast, log onto the Company’s website at www.adolor.com and click on “Investor Insights,” then “Webcast.” Click on the link and follow the prompts for registration and access.

About Adolor Corporation

Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products.

Adolor’s first approved product in the United States is ENTEREG® (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. ENTEREG is available for short-term use in hospitals registered under the E.A.S.E.™ Program. For more information on ENTEREG, including its full prescribing information, visit www.ENTEREG.com. In collaboration with GlaxoSmithKline (GSK), the Company launched ENTEREG in mid-2008.

The Company’s research and development pipeline includes: two novel delta opioid receptor agonists, currently in mid-stage clinical development in collaboration with Pfizer Inc. for chronic pain; two opioid receptor antagonists, ADL7445 and ADL5945, entering development for chronic opioid bowel dysfunction (OBD); and several opioid and non-opioid discovery programs.

For more information, visit www.adolor.com.

Adolor Corp. (MM) (NASDAQ:ADLR)
Historical Stock Chart
From Jun 2024 to Jul 2024